Leerink Partners Boosts Cardinal Health (NYSE:CAH) Price Target to $268.00

Cardinal Health (NYSE:CAH) had its price target lifted by stock analysts at Leerink Partners from $240.00 to $268.00 in a note issued to investors on Thursday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 18.14% from the company’s previous close.

CAH has been the topic of several other reports. Mizuho lifted their price objective on shares of Cardinal Health from $222.00 to $235.00 and gave the company an “outperform” rating in a report on Friday. Barclays started coverage on Cardinal Health in a report on Monday, December 8th. They issued an “overweight” rating and a $243.00 price target on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Cardinal Health in a research note on Wednesday, January 21st. UBS Group raised their price objective on Cardinal Health from $185.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Morgan Stanley boosted their target price on shares of Cardinal Health from $224.00 to $245.00 and gave the stock an “overweight” rating in a report on Thursday, January 29th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $239.93.

Cardinal Health Price Performance

CAH stock opened at $226.85 on Thursday. Cardinal Health has a 1-year low of $120.72 and a 1-year high of $230.81. The business has a 50-day moving average price of $206.92 and a 200 day moving average price of $179.97. The company has a market capitalization of $53.90 billion, a P/E ratio of 32.64, a PEG ratio of 1.51 and a beta of 0.64.

Cardinal Health (NYSE:CAH) last issued its earnings results on Thursday, February 5th. The company reported $2.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.32. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The company had revenue of $65.63 billion for the quarter, compared to analysts’ expectations of $64.88 billion. During the same period in the prior year, the business earned $1.93 EPS. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. On average, analysts anticipate that Cardinal Health will post 7.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardinal Health

Several institutional investors have recently added to or reduced their stakes in CAH. Strategy Asset Managers LLC purchased a new stake in Cardinal Health in the 3rd quarter valued at about $775,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Cardinal Health by 15.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,833 shares of the company’s stock worth $5,938,000 after buying an additional 5,030 shares during the period. Atle Fund Management AB increased its position in shares of Cardinal Health by 13.1% during the third quarter. Atle Fund Management AB now owns 30,297 shares of the company’s stock valued at $4,755,000 after acquiring an additional 3,500 shares during the last quarter. National Pension Service raised its stake in shares of Cardinal Health by 7.2% in the 3rd quarter. National Pension Service now owns 500,340 shares of the company’s stock valued at $78,533,000 after acquiring an additional 33,673 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in shares of Cardinal Health by 107.2% in the 2nd quarter. Baird Financial Group Inc. now owns 99,393 shares of the company’s stock worth $16,698,000 after acquiring an additional 51,416 shares during the last quarter. Institutional investors and hedge funds own 87.17% of the company’s stock.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.